EGFR and non-small cell lung carcinoma: These observations suggest that furmonertinib plus pemetrexed may have antitumor activity and acceptable tolerability in <i>EGFR</i> Ex19del lung adenocarcinoma, and may inform personalized approaches following resistance to first-line therapy in <i>EGFR</i>-sensitizing NSCLC.